We are international
• health professionals TEXT SIZE   
Bringing the Experts to You

The IMF is pleased to present the most comprehensive coverage of the XIth International Myeloma Workshop.

Day 1 Genetics Day 2 Novel treatment approaches
  Microenvironment   Frontline treatment of Myeloma
  Bone Disease   Debate I (Importance of CR)
      Oral presentations I
      Oral presentations II

Day 3 New treatment development Day 4 Oral presentations III
  Stem cell transplant   Debate II - Role of Transplant
  Other plasma cell dyscrasias   Current and Future Perspectives


KOS 2007
previous     next      view all

06.26.07   KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
Angelo Vacca, MD
Department of Internal Medicine and Clinical Oncology
University of Bari Medical School
Bari, Italy

06.26.07   KOS 2007: The Role of T-Cells in Multiple Myeloma
Douglas Joshua, MD
University of Sydney
Royal Prince Alfred and Concord Hospital
Camperdown, Australia

06.26.07   KOS 2007: Genetic Model of Multiple Myeloma
Ruben Carrasco, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
(Presentation given by Giovanni Tonon)

06.26.07   KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
Giovanni Tonon, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA

06.26.07   KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
Michio Kawano, MD
Laboratory of Cellular Signal Analysis
Graduate School of Medicine
Yamaguchi University
Ube, Japan

06.26.07   KOS 2007: Pathophysiology of Myeloma Bone Disease
Peter Croucher, MD
Section of Musculoskeletal Science
University of Sheffield Medical School
Sheffield, UK

06.26.07   KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
Los Angeles, CA, USA

06.26.07   KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
Evangelos Terpos, MD
Department of Hematology & Medical Research
251 General Airforce Hospital
Athens, Greece

06.26.07   KOS 2007: New Agents Targeting Myeloma Bone Disease
G. David Roodman
University of Pittsburgh
Pittsburgh, PA, USA

06.26.07   KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
Marta Chesi, MD
Comprehensive Cancer Center
Mayo Clinic Arizona
Scottsdale, AZ, USA

previous     next      view all